<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JIC</journal-id>
<journal-id journal-id-type="hwp">spjic</journal-id>
<journal-id journal-id-type="nlm-ta">J Intensive Care Med</journal-id>
<journal-title>Journal of Intensive Care Medicine</journal-title>
<issn pub-type="ppub">0885-0666</issn>
<issn pub-type="epub">1525-1489</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0885066611402154</article-id>
<article-id pub-id-type="publisher-id">10.1177_0885066611402154</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Analytic Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Pharmacology of Airway Management in Critical Care</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Consilvio</surname>
<given-names>Christian</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0885066611402154">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kuschner</surname>
<given-names>Ware G.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0885066611402154">2</xref>
<xref ref-type="corresp" rid="corresp1-0885066611402154"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lighthall</surname>
<given-names>Geoffrey K.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0885066611402154">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0885066611402154">
<label>1</label>Department of Anesthesia, Stanford University School of Medicine and Anesthesia Service, U.S. Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA</aff>
<aff id="aff2-0885066611402154">
<label>2</label>Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine and Medical Service, U.S. Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA</aff>
<author-notes>
<corresp id="corresp1-0885066611402154">Ware G. Kuschner, Medical Service, Pulmonary Section, U.S. Department of Veterans Affairs Palo Alto Health Care System, 3801 Miranda Avenue, Pulmonary Section, Mail Code: 111P, Palo Alto, CA 94304, USA. Email: <email>kuschner@stanford.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>5</issue>
<fpage>298</fpage>
<lpage>305</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>4</month>
<year>2010</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>9</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>9</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>This review provides an update on the pharmacology of airway management, emphasizing medications and management strategies widely used in an intensive care unit setting. Induction agents, muscle relaxants, opioids, sedative-hypnotics, and adjunctive agents are reviewed in the context of emergent airway management. Throughout this review, we emphasize the utility of considering a broad set of pharmacologic agents and approaches for airway management of the critically ill patient.</p>
</abstract>
<kwd-group>
<kwd>intubation</kwd>
<kwd>laryngoscopy</kwd>
<kwd>airway</kwd>
<kwd>anesthesia</kwd>
<kwd>sedation</kwd>
<kwd>muscle relaxant</kwd>
<kwd>neuromuscular blockade</kwd>
<kwd>pharmacology</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>September/October 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-0885066611402154">
<title>Introduction</title>
<p>Securing an airway, urgently or emergently, can be a stressful procedure for the experienced, as well as the inexperienced, laryngoscopist. Limited consideration may be given to the pharmacologic management of the patient during this hazardous procedure. Intubations of critically ill patients carry a high complication rate and should be done with personnel who are experienced with airway management.<sup><xref ref-type="bibr" rid="bibr1-0885066611402154">1</xref><xref ref-type="bibr" rid="bibr2-0885066611402154"/>–<xref ref-type="bibr" rid="bibr3-0885066611402154">3</xref></sup> While technical proficiency with laryngoscopy and endotracheal tube insertion are essential elements of expert airway management, an understanding of the pharmacology of drugs commonly indicated for airway management is also critically important for successful outcomes. Airway pharmacology requires an understanding of drugs' intended and untoward effects, an appreciation of the complicating effects of acute and chronic medical conditions, the physiologic changes associated with laryngoscopy, and recognition of postintubation patient care goals. This understanding is particularly vital in the intubation of critically ill patients who possess less physiologic reserve and who are likely to have more exaggerated responses to pharmacologic agents than healthier patients exposed to the same drugs.</p>
<p>Successful airway management in critical care demands aptitude in patient and airway evaluation, technical skill, situational awareness, and the flexibility to implement alternative strategies for ventilation and airway control at a moment’s notice. Proficiency in these aspects of airway management must be cultivated at the bedside. This broader landscape of airway management has been recently reviewed<sup><xref ref-type="bibr" rid="bibr4-0885066611402154">4</xref></sup> and is covered in many anesthesia texts. The purpose of this review is to provide an in-depth focus on the pharmacology of airway management, emphasizing medications and management strategies widely used in an intensive care unit (ICU) setting.</p>
<p>Unlike other fields of medicine where experimental and observational research have led to the development of well-defined clinical practice guidelines and treatment algorithms, limited guidance exists for airway management. Rather, careful consideration of patient problems, pharmacologic knowledge, and clinician experience form much of the knowledge base currently applied in airway management and constitutes the basis for many of the recommendations detailed in this review.</p>
</sec>
<sec id="section2-0885066611402154">
<title>Pharmacological Goals of Airway Management</title>
<p>The general pharmacologic goals in airway management are to render the patient unconscious, facilitate access to the larynx through skeletal muscle relaxation, and to assure patient comfort and hemodynamic stability during and after tracheal tube placement. Laryngoscopy and intubation result in important physiologic effects. In normal healthy individuals, instrumentation of the airway may cause blood pressure and heart rate elevations of 150% to 200% of resting values.<sup><xref ref-type="bibr" rid="bibr5-0885066611402154">5</xref></sup> Sympathetic outflow of this magnitude is very poorly tolerated by patients with cardiovascular disease and numerous other conditions.<sup><xref ref-type="bibr" rid="bibr6-0885066611402154">6</xref></sup> Some patients (eg, extreme respiratory distress, sepsis, and penetrating trauma) are already secreting high amounts of catecholamines and may not increase blood pressure in response to laryngoscopy, while others with intracranial pathology or aneurysmal disease may experience a high sympathetic outflow that can be fatal.</p>
<p>For the purpose of this discussion, relevant medications will be categorized as induction agents, muscle relaxants, or adjunct agents.</p>
</sec>
<sec id="section3-0885066611402154">
<title>Induction Agents</title>
<sec id="section4-0885066611402154">
<title>Overview</title>
<p>Induction agents are medications used to induce unconsciousness in the patient prior to administering a muscle relaxant and subsequent intubation. An awake and unparalyzed patient generally cannot tolerate a direct laryngoscopy. Administering a muscle relaxant without an induction agent to render the patient unconsciousness would be very distressing to the patient and is unacceptable under most circumstances.<sup><xref ref-type="bibr" rid="bibr7-0885066611402154">7</xref></sup> Induction agents used in an ICU setting include etomidate, propofol, thiopental and ketamine. Each agent exerts unique hemodynamic effects and has a unique side effect-profile (<xref ref-type="table" rid="table1-0885066611402154">Table 1</xref>
). Induction agents may have recommended ranges of “typical induction doses.” However, appropriate dosages vary markedly according to patient characteristics and clinical situations. For instance, a 90-year-old man will generally require far less induction agent than an 18-year-old, as the pharmacokinetics of drugs and pharmacodynamics of patients will change with age. A patient who is barely conscious from hypercarbia will likely be induced with far less medication than a chronic opiate user.</p>
<table-wrap id="table1-0885066611402154" position="float">
<label>Table 1.</label>
<caption>
<p>Induction Agents Used in Airway Management<sup><xref ref-type="table-fn" rid="table-fn2-0885066611402154">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0885066611402154" xlink:href="10.1177_0885066611402154-table1.tif"/>
<table>
<thead>
<tr>
<th>Induction Agents</th>
<th>Typical Induction Dose (mg/kg)</th>
<th>Duration of Action (Minutes)</th>
<th>Blood Pressure</th>
<th>Respiratory Depression</th>
<th>Special Properties</th>
<th>Cautions &amp; Contradictions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propofol</td>
<td>1.5-2.5</td>
<td>5-10</td>
<td>↓↓</td>
<td>↑↑↑</td>
<td> </td>
<td>Pain on injection</td>
</tr>
<tr>
<td>Ketamine</td>
<td>1.0-2.0</td>
<td>10-20</td>
<td>↑↑</td>
<td>0</td>
<td>Bronchodilator</td>
<td>↑ICP, ↑CMRO<sub>2</sub>
</td>
</tr>
<tr>
<td>Etomidate</td>
<td>0.2-0.3</td>
<td>3-12</td>
<td>0</td>
<td>↑↑</td>
<td> </td>
<td>Adrenal suppression, Pain on injection</td>
</tr>
<tr>
<td>Thiopental</td>
<td>3.0-5.0</td>
<td>5-10</td>
<td>↓</td>
<td>↑↑↑</td>
<td>↓ICP, ↓CMRO<sub>2</sub>
</td>
<td>Precipitates with nondepolarizing relaxants</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0885066611402154">
<p>Abbreviations: ICP, intracranial pressure; CMRO<sub>2</sub>, cerebral metabolic rate.</p>
</fn>
<fn id="table-fn2-0885066611402154">
<p>
<sup>a</sup> Properties of common induction agents are compared. Upward and downward arrows indicate increases and decreases in the parameters listed.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0885066611402154">
<title>Etomidate</title>
<p>Etomidate is a carboxylated imidazole that depresses the reticular activating system acting on gamma-butyric acid (GABA) receptors blocking neuroexcitation. Etomidate is dissolved in propylene glycol which causes a high incidence of pain on injection. It also can have a disinhibitory effect on central nervous system extrapyramidal motor activities often causing a characteristic myoclonus upon administration.<sup><xref ref-type="bibr" rid="bibr8-0885066611402154">8</xref></sup>
</p>
<p>The usual induction dose of etomidate is 0.2 to 0.4 mg/kg. The time to onset is about 15 to 45 seconds and the duration of effect is 3 to 12 minutes. Etomidate has no analgesic effects and causes a mild increase in airway resistance and no effect on intracranial pressure. It has minimal effects on the cardiovascular system: myocardial contractility and cardiac output are unaffected.<sup><xref ref-type="bibr" rid="bibr8-0885066611402154">8</xref></sup> Etomidate inhibits the activity of 11-<italic>B</italic>-hydroxylase, an enzyme involved in cortisol and aldosterone synthesis.<sup><xref ref-type="bibr" rid="bibr9-0885066611402154">9</xref></sup> Even a single dose can result in a decreased level of circulating cortisol persisting for 2 to 24 hours.<sup><xref ref-type="bibr" rid="bibr10-0885066611402154">10</xref></sup> Etomidate also has been shown to affect circulating lymphocyte levels and levels of interleukin (IL)-6 and IL-10 and other pro-inflammatory mediators involved in sepsis.<sup><xref ref-type="bibr" rid="bibr11-0885066611402154">11</xref></sup>
</p>
<p>In a retrospective review of 152 patients with septic shock who underwent a corticotropin stimulation test after a mean interval of 7 hours after induction, 76% of those who received etomidate had evidence of adrenal insufficiency vs. 51% who were managed without etomidate.<sup><xref ref-type="bibr" rid="bibr12-0885066611402154">12</xref></sup> In a similar study of patients with trauma where the vast majority of cosyntropin tests were administered over 48 hours following intubation, a nonresponder rate of 60% was still found.<sup><xref ref-type="bibr" rid="bibr13-0885066611402154">13</xref></sup>A prospective study of nonseptic critically ill patients showed a high degree of adrenal suppression (80%) at 12 hours following etomidate, but resolving by 48 hours following administration.<sup><xref ref-type="bibr" rid="bibr14-0885066611402154">14</xref></sup> A post hoc analysis of patients enrolled in the CORTICUS trial found an association between etomidate use and reduced responsiveness to corticotropin and mortality, while a prospective observational study of etomidate use on septic patients in the Emergency Department found no significant increase in either length of stay or morality in those who received etomidate for intubations.<sup><xref ref-type="bibr" rid="bibr15-0885066611402154">15</xref><xref ref-type="bibr" rid="bibr16-0885066611402154"/>–<xref ref-type="bibr" rid="bibr17-0885066611402154">17</xref></sup>
</p>
<p>In summary, the minimal cardiovascular side effect profile of etomidate makes it an attractive induction agent, especially when used to sedate an acutely ill patient. However, concerns about adrenal suppression associated with the agent should prompt consideration of alternatives and anticipation of hemodynamic compromise. When etomidate is used in septic patients, recognition and treatment of adrenal insufficiency is of utmost importance.</p>
</sec>
<sec id="section6-0885066611402154">
<title>Propofol</title>
<p>Propofol is an alkylphenol compound mixed in an emulsion containing soybean oil, glycerol, and egg lecithin. The induction dose in healthy adults is 1.5 to 2.5 mg/kg, while elderly and acutely ill patients will generally need a lower dose. The onset of effect is 15 to 40 seconds and the duration of effect is about 3 to 5 minutes. Propofol also induces a depression of the upper airway reflexes and because of this it deserves consideration when attempting to intubate without a muscle relaxant.<sup><xref ref-type="bibr" rid="bibr18-0885066611402154">18</xref></sup> However, propofol has significant dose-dependent respiratory and cardiovascular depressant effects. It has direct myocardial depressant and systemic vascular resistance effects, decreasing the mean arterial blood pressure by an average of 10 mm Hg on induction. It also alters the baroreflex mechanism which results in a smaller increase in heart rate for a concurrent decrease in arterial blood pressure.<sup><xref ref-type="bibr" rid="bibr19-0885066611402154">19</xref></sup> Use of propofol has emerged as an independent predictor of hypotension following induction of anesthesia in patients of all ages and physical classes.<sup><xref ref-type="bibr" rid="bibr2-0885066611402154">2</xref></sup>Further, hypotension following intubation is a strong independent predictor of mortality in critically ill patients requiring emergency airway management.<sup><xref ref-type="bibr" rid="bibr3-0885066611402154">3</xref></sup>Propofol should, therefore, be avoided in hypotensive patients requiring emergent intubation.</p>
</sec>
<sec id="section7-0885066611402154">
<title>Ketamine</title>
<p>Ketamine is an arylcyclohexylamine that is structurally related to phencyclidine. It produces dose-dependent central nervous system depression leading to a state of “dissociative anesthesia” causing profound analgesia and amnesia. It functionally dissociates the thalamus from the limbic system. Ketamine acts as an agonist on a variety of receptors, including the <italic>N</italic>-methyl-<sc>d</sc>-asparate receptors at the GABA receptor complex, and opioid receptors in the insular cortex, putamen, and thalamus. It will stimulate catecholamine receptors causing an increase in heart rate, myocardial contractility, and the mean arterial blood pressure, making it very useful in situations of cardiovascular collapse.<sup><xref ref-type="bibr" rid="bibr20-0885066611402154">20</xref></sup>Less prominent actions include production of vascular nitric oxide which increases vascular resistance and inhibition of nicotinic acetylcholine receptors.</p>
<p>The induction dose is 1 to 2 mg/kg intravenously in the normal patient. Like all induction agents, the dose should be adjusted down in the compromised patient. The time of onset is about 45 to 60 seconds and the duration of effect is about 10 to 20 minutes. An untoward effect of ketamine is hallucinosis; the latter can be attenuated by administration of a benzodiazepine if tolerated.<sup><xref ref-type="bibr" rid="bibr21-0885066611402154">21</xref></sup> While mainly discussed as an induction agent here, the analgesic properties and minimal respiratory depression at lower doses (0.25-0.5 mg/ kg) have led to its extensive use for dressing changes and wound care.</p>
<p>If administered as a single agent (ie, no concomitant use of opioids or muscle relaxants), ketamine will not cause apnea or a loss of protective reflexes in most individuals. This can be advantageous in situations when intubation is attempted with topical anesthesia and brief loss of consciousness. Ketamine is also a potent bronchodilator, making it an excellent drug choice for patients with severe asthma. Ketamine increases pulmonary artery pressure and myocardial work and should generally be avoided in patients with coronary artery disease, hypertension, congestive heart failure, and arterial aneurysms.<sup><xref ref-type="bibr" rid="bibr22-0885066611402154">22</xref></sup> Ketamine also increases cerebral oxygen consumption, cerebral blood flow, and intracranial pressure (ICP), making it a poor choice for induction for patients with intracranial lesions or closed-head trauma in which high ICP may be present.</p>
</sec>
<sec id="section8-0885066611402154">
<title>Thiopental</title>
<p>Thiopental is a barbiturate which depresses the reticular activating system by enhancing the transmission of the inhibitory neurotransmitter GABA. Thiopental is a thiobarbiturate that is supplied as a sodium salt, thus requiring the user to prepare a working solution from the stock. Of note, when added to an acidic solution (eg, pancuronium or rocuronium) it will precipitate. Intra-arterial injection can cause crystal formation in the arterioles leading to tissue necrosis.</p>
<p>The induction dose is 3 to 5 mg/kg in healthy adults. The onset of effect is less than 30 seconds and the duration of effect is 5 to 10 minutes. It produces a dose-dependent decrease in cerebral metabolic rate and cerebral blood flow making it an ideal choice for patients with increased ICP and brain injury. Thiopental has no analgesic effects. It causes hypotension from venodilation and has negative inotropic effects.<sup><xref ref-type="bibr" rid="bibr23-0885066611402154">23</xref></sup> Thiopental can cause histamine release that can induce or exacerbate bronchospasm.<sup><xref ref-type="bibr" rid="bibr24-0885066611402154">24</xref></sup> Thiopental may be a poor choice in sepsis. It has been shown to suppress white blood cell recruitment, activation, and activity in vitro and in vivo,<sup><xref ref-type="bibr" rid="bibr25-0885066611402154">25</xref></sup> but there are no reports of increased mortality in septic patients receiving a thiopental induction.</p>
</sec>
</sec>
<sec id="section9-0885066611402154">
<title>Muscle Relaxants</title>
<sec id="section10-0885066611402154">
<title>Overview</title>
<p>Laryngoscopy and intubation requires movement of the head and neck to an unnatural and uncomfortable position, and elimination of strong protective reflexes. Accordingly, agents that impair neuromuscular activity are commonly used to facilitate tracheal intubation. The ideal muscle relaxant for emergency airway management would have a quick onset of dense paralysis, a short duration, and no significant side effects. Unfortunately, this ideal muscle relaxant does not yet exist, so the practitioner must prioritize these factors in the selection and dosing of an agent. Muscle relaxants are typically classified as either depolarizing (of which succinylcholine is the sole drug) or nondepolarizing neuromuscular blockers (<xref ref-type="table" rid="table2-0885066611402154">Table 2</xref>
).</p>
<table-wrap id="table2-0885066611402154" position="float">
<label>Table 2.</label>
<caption>
<p>Muscle Relaxants Used in Airway Management<sup><xref ref-type="table-fn" rid="table-fn3-0885066611402154">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-0885066611402154" xlink:href="10.1177_0885066611402154-table2.tif"/>
<table>
<thead>
<tr>
<th>Muscle Relaxants</th>
<th>Type</th>
<th>Typical Induction Dose (mg/kg)</th>
<th>Time to Onset (Minutes)</th>
<th>Duration to 25% Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Succinylcholine</td>
<td>Depolarizer</td>
<td>1-1.5</td>
<td>1-1.5</td>
<td>6-8</td>
</tr>
<tr>
<td>Rocuronium</td>
<td>Nondepolarizer</td>
<td>0.9-1.2</td>
<td>1-1.5</td>
<td>30-40</td>
</tr>
<tr>
<td>Vecuronium</td>
<td>Nondepolarizer</td>
<td>0.08-.12</td>
<td>3-4</td>
<td>35-45</td>
</tr>
<tr>
<td>Cisatracurium</td>
<td>Nondepolarizer</td>
<td>0.1-0.15</td>
<td>5-7</td>
<td>30-45</td>
</tr>
<tr>
<td>Pancuronium</td>
<td>Nondepolarizer</td>
<td>0.08-0.12</td>
<td>2-4</td>
<td>60-120</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0885066611402154">
<p>
<sup>a</sup> Typical times to onset and recovery, and induction doses of common muscle relaxants are compared. Recovery time is defined as the time to regain 25% of baseline movement elicited by electrical stimulation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0885066611402154">
<title>Succinylcholine</title>
<p>Succinylcholine is a depolarizing muscle relaxant consisting of a physical structure of 2 joined acetylcholine (ACh) molecules. Succinylcholine binds to Ach receptors generating a muscle action by the opening of nicotinic Ach receptors. The latter receptors are ligand-gated nonselective ion channels, in which sodium and calcium ions enter the sarcomere while potassium ions exit the cell. These channels then close and cannot trigger muscle contraction as long as succinylcholine continues to bind to the receptor.<sup><xref ref-type="bibr" rid="bibr26-0885066611402154">26</xref></sup>
</p>
<p>Succinylcholine is often the best choice for rapid sequence intubations due to its rapid onset of action (30-60 seconds) and its short duration of action (about 10 minutes).<sup><xref ref-type="bibr" rid="bibr27-0885066611402154">27</xref></sup> The short duration of action provides some security if intubation is unexpectedly impossible since the patient’s spontaneous ventilation will often return after several minutes. The duration of action can be prolonged in hypothermia, genetically low pseudocholinesterase levels, pregnancy, liver disease, and renal failure.<sup><xref ref-type="bibr" rid="bibr28-0885066611402154">28</xref></sup>
</p>
<p>The intubating dose of succinylcholine is 1 to 1.5 mg/kg. The drug can also be administered intramuscularly at a dose of 4 to 5 mg/kg, often with incomplete paralysis. The onset of paralysis with succinylcholine is often seen with visible whole body muscle contractions called fasiculations.</p>
<p>Succinylcholine has important side effects and contraindications that are listed in <xref ref-type="table" rid="table3-0885066611402154">Table 3</xref>
. Succinylcholine will stimulate Ach receptors at the neuromuscular junction and in the parasympathetic and sympathetic nervous systems. A metabolite of succinylcholine, succinylmonocholine, can activate Ach receptors in the sinoatrial node causing bradycardia. This is particularly common in children.<sup><xref ref-type="bibr" rid="bibr29-0885066611402154">29</xref></sup> In adults, bradycardia is commonly seen if a second dose of succinylcholine is administered. It is advisable to co-administer atropine with a second dose.<sup><xref ref-type="bibr" rid="bibr26-0885066611402154">26</xref></sup>
</p>
<table-wrap id="table3-0885066611402154" position="float">
<label>Table 3.</label>
<caption>
<p>Contraindications to Succinylcholine</p>
</caption>
<graphic alternate-form-of="table3-0885066611402154" xlink:href="10.1177_0885066611402154-table3.tif"/>
<table>
<tbody>
<tr>
<td>Burns</td>
</tr>
<tr>
<td>Spinal cord injury</td>
</tr>
<tr>
<td>Old stroke</td>
</tr>
<tr>
<td>Tetanus</td>
</tr>
<tr>
<td>Prolonged immobilization</td>
</tr>
<tr>
<td>Myopathies</td>
</tr>
<tr>
<td>Guillain-Barre syndrome</td>
</tr>
<tr>
<td>Malignant hyperthermia history</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>During a succinylcholine-induced depolarization, the serum potassium will normally increase by 0.5 mEq/L.<sup><xref ref-type="bibr" rid="bibr30-0885066611402154">30</xref></sup> Skeletal muscles of patients that have had denervation or disuse injuries (including burns, neurological disorders, prolonged bed rest) have a characteristic upregulation of Ach receptors at extrajunctional sites that magnify the effect of Ach on potassium release, producing asystole in some cases.<sup><xref ref-type="bibr" rid="bibr30-0885066611402154">30</xref>,<xref ref-type="bibr" rid="bibr31-0885066611402154">31</xref></sup> A list of these cases where succinylcholine is contraindicated and where nondepolarizing agents is preferred is provided in <xref ref-type="table" rid="table3-0885066611402154">Table 3</xref>.<sup><xref ref-type="bibr" rid="bibr32-0885066611402154">32</xref></sup> Succinylcholine is also a trigger of malignant hyperthermia, a genetic hypermetabolic disorder of skeletal muscle which is fatal without therapy with dantrolene. It must be avoided in patients with a personal or family history of this disorder.</p>
</sec>
<sec id="section12-0885066611402154">
<title>Nondepolarizing Agents</title>
<p>In contrast to succinylcholine which blocks neuromuscular transmission by initially activating the nicotinic receptors, the nondepolarizing agents act as classic receptor antagonists. Weight-based potencies (mg/kg) are defined by the 95% effective dose (ED<sub>95</sub>); that is, the amount of drug needed to suppress 75% of baseline muscle strength in 95% of a test population. Intubation doses are typically 2 to 3 times the ED<sub>95</sub>. Using 3 to 4 times the ED<sub>95</sub> can accelerate the onset of most agents, however at the expense of more prolonged muscle paralysis.<sup><xref ref-type="bibr" rid="bibr33-0885066611402154">33</xref><xref ref-type="bibr" rid="bibr34-0885066611402154"/>–<xref ref-type="bibr" rid="bibr35-0885066611402154">35</xref></sup> Regardless of dose, no drug is characterized by the fast onset and offset of succinylcholine.<sup><xref ref-type="bibr" rid="bibr36-0885066611402154">36</xref></sup>
</p>
<p>A nondepolarizing muscle relaxant’s reversal of block is dependent on redistribution and slow metabolism. Administration of an acetylcholinesterase inhibitor, the enzyme which degrades Ach, will increase the amount of Ach available in the synaptic cleft that can compete with the nondepolarizing muscle relaxant for available Ach receptors, increasing the rate of “block reversal.”<sup><xref ref-type="bibr" rid="bibr37-0885066611402154">37</xref></sup> However, this requires a certain amount of spontaneous reversal and ensure reversal immediately after an intubating dose. This cannot be emphasized strongly enough.</p>
</sec>
<sec id="section13-0885066611402154">
<title>Rocuronium</title>
<p>Rocuronium is a nondepolarizing muscle relaxant that can be used at a dosage of 0.9 to 1.2 mg/kg for rapid sequence intubation. The onset of action (60-90 seconds) is faster than other nondepolarizers run at a similar ED95 but is slightly longer than succinylcholine.<sup><xref ref-type="bibr" rid="bibr36-0885066611402154">36</xref></sup> Nonetheless, rocuronium is the most frequently used nondepolarizer for emergency intubations. The onset and duration of rocuronium and other nondepolarizing relaxants are compared in <xref ref-type="table" rid="table2-0885066611402154">Table 2</xref>. The drawback of rocuronium compared to succinylcholine is its longer duration of action. Thus, after giving an induction dose of rocuronium, if intubation proves to be difficult, the patient will not regain the ability to spontaneously breathe for an extended period of time (up to an hour).</p>
</sec>
<sec id="section14-0885066611402154">
<title>Vecuronium</title>
<p>Vecuronium is a nondepolarizing muscle relaxant. The intubating dose is 0.08 to 0.12 mg/kg and its onset of action is about 3 minutes, making it a poor choice for rapid sequence intubation. It primarily undergoes biliary and renal excretion and its duration of action is slightly prolonged in renal failure. Long-term administration of vecuronium has led to prolonged neuromuscular blockade in ICU patients possibly due to a 3-hydroxy metabolite.</p>
</sec>
<sec id="section15-0885066611402154">
<title>Cisatracurium</title>
<p>Cisatracurium is a nondepolarizing muscle relaxant that is metabolized in the plasma by Hofmann elimination making metabolism independent of kidney or liver function. The intubating dose of cisatracurium is 0.1-0.15 mg/kg, with an onset of 3 minutes and its duration is 30 to 45 minutes, making it a poor choice for rapid sequence intubations. Because the elimination of cisatracurium does not depend on the end organ function of a patient, it is the ideal drug for the administration of paralytic infusions in the ICU setting.</p>
</sec>
<sec id="section16-0885066611402154">
<title>Pancuronium</title>
<p>Pancuronium is a nondepolarizing muscle relaxant. The intubating dose is 0.08 to 0.12 mg/kg providing intubation conditions in 2 to 3 minutes, making it a poor choice for rapid sequence intubation. It also has a long duration of action after an intubating dose—between 60 to 120 minutes. It is metabolized by the liver and excreted by the kidneys. Its elimination is prolonged in renal failure. Pancuronium can cause hypertension and tachycardia via vagal blockade and catecholamine release increasing the risk of ventricular dysrhythmias and myocardial ischemia in susceptible patients.</p>
</sec>
<sec id="section17-0885066611402154">
<title>Sugammadex—a Muscle Relaxant Reversal Agent</title>
<p>Sugammadex terminates the action of neuromuscular blockers by direct encapsulation, leading to fast effective reversal.<sup><xref ref-type="bibr" rid="bibr38-0885066611402154">38</xref></sup> A phase II study of 4 mg/kg of suggamadex showed reversal of moderately profound rocuronium induced blockade (1.8 minutes) versus neostigmine/glycopyrrolate (17.4 minutes), with minimal side effects.<sup><xref ref-type="bibr" rid="bibr39-0885066611402154">39</xref>,<xref ref-type="bibr" rid="bibr40-0885066611402154">40</xref></sup> Although there has not yet been a side-by-side comparison of rocuronium/sugammadex with succinylcholine, current clinical data suggest that this pairing may provide a reasonable alternative to the latter for emergency airway management. In principle, removal of the free unbound paralytic should increase the release and diffusion away from the synaptic cleft of the bound form. Whether this pharmacokinetic mechanism creates any clinical advantage for airway management (as opposed to surgical use) remains to be seen. The drug is not yet Food and Drug Administration (FDA) approved.</p>
</sec>
</sec>
<sec id="section18-0885066611402154">
<title>Opioids and Adjuncts</title>
<p>Agents from other drug classes can help facilitate the goals of patient comfort and hemodynamic stability during airway management. Opioids and benzodiazepines are commonly used to relieve pain and distress in the period surrounding intubation. Both classes of agents are useful as premedications that can decrease the total dose needed of an induction agent, and fentanyl blunts the physiologic response to laryngoscopy. Lidocaine and esmolol are other options to blunt the sympathetic surge during intubation that may be appropriate in different patient populations (<xref ref-type="table" rid="table4-0885066611402154">Table 4</xref>
).</p>
<table-wrap id="table4-0885066611402154" position="float">
<label>Table 4.</label>
<caption>
<p>Adjunct Agents Used for Patient Comfort and Hemodynamic Control in Airway Management<sup><xref ref-type="table-fn" rid="table-fn4-0885066611402154">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table4-0885066611402154" xlink:href="10.1177_0885066611402154-table4.tif"/>
<table>
<thead>
<tr>
<th>Adjunct Agents</th>
<th>Drug Class</th>
<th>Typical Dose</th>
<th>Respiratory Depression</th>
<th>Class and Typical Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midazolam</td>
<td>Benzodiazepine</td>
<td>0.5-2 mg</td>
<td>Yes (opioid synergy)</td>
<td>Anxiolytic</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Opioid</td>
<td>1.5-5 mcg/kg</td>
<td>Yes</td>
<td>Induction adjunct. Blunts sensation of intubation, lowers sympathetic discharge</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>Local anesthetics</td>
<td>1.5-2.5 mg/kg</td>
<td>No</td>
<td>Blunts sensation of intubation, lowers sympathetic discharge</td>
</tr>
<tr>
<td>Esmolol</td>
<td>
<italic>B</italic>
<sub>1</sub> Adrenergic antagonist</td>
<td>1-2 mg/kg</td>
<td>No</td>
<td>Blunts reaction to sympathetic surge during intubation</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0885066611402154">
<p>
<sup>a</sup> Commonly used agents that improve patient comfort and hemodynamic stability during intubation are presented. Classes, reasons for use, doses, and degree of respiratory depression are indicated for each drug or class of agent.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section19-0885066611402154">
<title>Fentanyl</title>
<p>Fentanyl is a synthetic opioid producing dose-dependent analgesia, sedation, and respiratory depression. It is useful as an adjunct agent during induction where doses of 1.5 to 5 μg/kg 3 minutes prior to induction can decrease the sympathetic surge associated with laryngoscopy.<sup><xref ref-type="bibr" rid="bibr41-0885066611402154">41</xref></sup> Smaller incremental doses of 25 to 50 mcg (in adults) can attenuate cough and other protective reflexes and become a valuable tool to facilitate awake fiberoptic intubation. Fentanyl will decrease the required dose of another induction agent (propofol, thiopental) to achieve loss of consciousness.<sup><xref ref-type="bibr" rid="bibr42-0885066611402154">42</xref></sup> However, rapid boluses of even 2 mcg/kg fentanyl can lead to chest wall rigidity making both spontaneous ventilation and mask ventilation impossible without muscle relaxation.<sup><xref ref-type="bibr" rid="bibr43-0885066611402154">43</xref></sup>
</p>
</sec>
<sec id="section20-0885066611402154">
<title>Midazolam</title>
<p>Midazolam, a benzodiazepine, is an effective anxiolytic medication. It causes sedation and amnesia through GABA receptor effects. A dose of 0.5 to 2 mg can be bolused or slowly titrated to desired anxiolytic clinical effect. Midazolam has no analgesic properties. It can cause modest hypotension, decreasing the blood pressure 10% to 25%. In combination with opioids, midazolam can induce profound respiratory depression.<sup><xref ref-type="bibr" rid="bibr44-0885066611402154">44</xref></sup>
</p>
<p>There are certain patient populations where administration of fentanyl or midazolam as a premedication would be dangerous. Some unstable or severely compromised patients are unable to tolerate any sort of depressant. An example would be a patient with severe obstructive sleep apnea where a respiratory depressant may cause dangerous obstruction. Also, for fentanyl to blunt the response to laryngoscopy, it takes five minutes for an appropriate dose of fentanyl to reach peak effect. There are some situations where intubation needs to occur in less time. Medications such as intravenous lidocaine and esmolol may be more appropriate in these situations.</p>
</sec>
<sec id="section21-0885066611402154">
<title>Lidocaine and Local Anesthetics</title>
<p>Intravenous lidocaine has been used with variable success to blunt the hemodynamic and airway responses to tracheal instrumentation administered in a dose of 1.5 to 2.5 mg/kg IV at least 3 minutes before induction.<sup><xref ref-type="bibr" rid="bibr45-0885066611402154">45</xref></sup> The toxic side effects of lidocaine that might be encountered at lower doses include lightheadedness, tinnitus, and numbness of the tongue. Higher doses may cause seizures and eventually cardiovascular depression.<sup><xref ref-type="bibr" rid="bibr46-0885066611402154">46</xref></sup> At the doses in the range of 2 mg/kg, lidocaine is safe and can be an effective means of blunting the sometimes deleterious hemodynamic consequences of laryngoscopy.</p>
<p>While lidocaine is the only local anesthetic used intravenously in airway management, a number of local anesthetics have been administered topically to the oropharynx to facilitate awake intubation; however, lidocaine and benzocaine are the most widely used and are likely to be the only agents available to intensivists for this purpose. Benzocaine spray has the fastest onset of activity; however, there is a significant dose-related risk of methemoglobinemia that has been reported repeatedly in multiple settings.<sup><xref ref-type="bibr" rid="bibr47-0885066611402154">47</xref><xref ref-type="bibr" rid="bibr48-0885066611402154"/><xref ref-type="bibr" rid="bibr49-0885066611402154"/><xref ref-type="bibr" rid="bibr50-0885066611402154"/><xref ref-type="bibr" rid="bibr51-0885066611402154"/>–<xref ref-type="bibr" rid="bibr52-0885066611402154">52</xref></sup> Factors related to development of methemoglobinemia include individual variability, low therapeutic index, over dosage, and erratic delivery from the spray canister.<sup><xref ref-type="bibr" rid="bibr53-0885066611402154">53</xref></sup>This safety risk has led to its removal from the US Veterans Affairs national formulary.<sup><xref ref-type="bibr" rid="bibr54-0885066611402154">54</xref>,<xref ref-type="bibr" rid="bibr55-0885066611402154">55</xref></sup> Fortunately, lidocaine has proven to be a safer and equally efficacious alternative to benzocaine,<sup><xref ref-type="bibr" rid="bibr56-0885066611402154">56</xref>,<xref ref-type="bibr" rid="bibr57-0885066611402154">57</xref></sup> with a potentially greater therapeutic window<sup><xref ref-type="bibr" rid="bibr58-0885066611402154">58</xref>,<xref ref-type="bibr" rid="bibr59-0885066611402154">59</xref></sup>
</p>
<p>There is some flexibility with how local anesthetics can be delivered prior to intubation. While preparing fiberoptic or other airway equipment, one can begin topicalization “hands free” by administration of lidocaine (4 mL of 4%) via an oxygen mask nebulizer system. After 5 to 10 minutes, the density of anesthesia is increased by direct spraying of the posterior pharynx with lidocaine via an atomizer until the gag response is adequately suppressed.</p>
</sec>
<sec id="section22-0885066611402154">
<title>Esmolol</title>
<p>Esmolol is a short-acting selective β<sub>1</sub>-antagonist that primarily reduces heart rate, and, to a lesser extent, blood pressure. It has a half-life of 2 minutes and undergoes hydrolysis by red blood cell esterases. A dose of 1 to 2 mg/kg is effective in attenuating the stimulation associated with laryngoscopy. Esmolol has been shown to be more effective than lidocaine at controlling the acute hemodynamic response following laryngoscopy, but, other studies have shown that only the combination of lidocaine and esmolol attenuated both heart rate and blood pressure response to tracheal intubation.<sup><xref ref-type="bibr" rid="bibr60-0885066611402154">60</xref>,<xref ref-type="bibr" rid="bibr61-0885066611402154">61</xref></sup>
</p>
</sec>
</sec>
<sec id="section23-0885066611402154">
<title>Summary</title>
<p>The skill of airway management involves more than laryngoscopy and insertion of a tracheal tube. In addition to technical proficiency with laryngoscopy and tube insertion, careful consideration of both patient physiology and drug pharmacology is essential in developing an emergent airway-management strategy. The experienced manager of airways must understand the spectrum of medications available for use in the setting of airway management and the ways each agent can contribute to either success or failure in caring for different types of patients.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgement</title>
<p>The authors appreciate a critical review of this work by Drs Kevin Fish and Iqbal Mirza.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0885066611402154">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0885066611402154">
<label>Funding</label>
<p>The authors received no financial support for the research and/or authorship of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0885066611402154">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaber</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Amraoui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lefrant</surname>
<given-names>JY</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical practice and risk factors for immediate complications of endotracheal intubation in the intensive care unit: a prospective, multiple-center study</article-title>. <source>Crit Care Med</source>. <year>2006</year>;<volume>34</volume>(<issue>9</issue>):<fpage>2355</fpage>–<lpage>2361</lpage>.</citation>
</ref>
<ref id="bibr2-0885066611402154">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reich</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Hossain</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Krol</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictors of hypotension after induction of general anesthesia</article-title>. <source>Anesth Analg</source>. <year>2005</year>;<volume>101</volume>(<issue>3</issue>):<fpage>622</fpage>–<lpage>628</lpage>, <comment>table of contents</comment>.
</citation>
</ref>
<ref id="bibr3-0885066611402154">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Matthay</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>NH</given-names>
</name>
</person-group>. <article-title>Death and other complications of emergency airway management in critically ill adults. A prospective investigation of 297 tracheal intubations</article-title>. <source>Anesthesiology</source>. <year>1995</year>;<volume>82</volume>(<issue>2</issue>):<fpage>367</fpage>–<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr4-0885066611402154">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walz</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Zayaruzny</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heard</surname>
<given-names>SO</given-names>
</name>
</person-group>. <article-title>Airway management in critical illness</article-title>. <source>Chest</source>. <year>2007</year>;<volume>131</volume>(<issue>2</issue>):<fpage>608</fpage>–<lpage>620</lpage>.</citation>
</ref>
<ref id="bibr5-0885066611402154">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forbes</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Dally</surname>
<given-names>FG</given-names>
</name>
</person-group>. <article-title>Acute hypertension during induction of anaesthesia and endotracheal intubation in normotensive man</article-title>. <source>Br J Anaesth</source>. <year>1970</year>;<volume>42</volume>(<issue>7</issue>):<fpage>618</fpage>–<lpage>624</lpage>.</citation>
</ref>
<ref id="bibr6-0885066611402154">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fox</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Sklar</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Villanueva</surname>
<given-names>R</given-names>
</name>
<name>
<surname>King</surname>
<given-names>BD</given-names>
</name>
</person-group>. <article-title>Complications related to the pressor response to endotracheal intubation</article-title>. <source>Anesthesiology</source>. <year>1977</year>;<volume>47</volume>(<issue>6</issue>):<fpage>524</fpage>–<lpage>525</lpage>.</citation>
</ref>
<ref id="bibr7-0885066611402154">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranta</surname>
<given-names>SO</given-names>
</name>
<name>
<surname>Laurila</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Saario</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ali-Melkkilä</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hynynen</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Awareness with recall during general anesthesia: incidence and risk factors</article-title>. <source>Anesth Analg</source>. <year>1998</year>;<volume>86</volume>(<issue>5</issue>):<fpage>1084</fpage>–<lpage>1089</lpage>.</citation>
</ref>
<ref id="bibr8-0885066611402154">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Hamme</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ghoneim</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Ambre</surname>
<given-names>JJ</given-names>
</name>
</person-group>. <article-title>Pharmacokinetics of etomidate, a new intravenous anesthetic</article-title>. <source>Anesthesiology</source>. <year>1978</year>;<volume>49</volume>(<issue>4</issue>):<fpage>274</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr9-0885066611402154">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>White</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Inhibition of adrenal steroidogenesis by the anesthetic etomidate</article-title>. <source>N Engl J Med</source>. <year>1984</year>;<volume>310</volume>(<issue>22</issue>):<fpage>1415</fpage>–<lpage>1421</lpage>.</citation>
</ref>
<ref id="bibr10-0885066611402154">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hildreth</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Mejia</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Dart</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>DE</given-names>
</name>
</person-group>. <article-title>Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study</article-title>. <source>J Trauma</source>. <year>2008</year>;<volume>65</volume>(<issue>3</issue>):<fpage>573</fpage>–<lpage>579</lpage>.</citation>
</ref>
<ref id="bibr11-0885066611402154">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jameson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Desborough</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Bryant</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>GM</given-names>
</name>
</person-group>. <article-title>The effect of cortisol suppression on interleukin-6 and white blood cell responses to surgery</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>1997</year>;<volume>41</volume>(<issue>2</issue>):<fpage>304</fpage>–<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr12-0885066611402154">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohammad</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Afessa</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Finkielman</surname>
<given-names>JD</given-names>
</name>
</person-group>. <article-title>The incidence of relative adrenal insufficiency in patients with septic shock after the administration of etomidate</article-title>. <source>Crit Care</source>. <year>2006</year>;<volume>10</volume>(<issue>4</issue>):<fpage>R105</fpage>.</citation>
</ref>
<ref id="bibr13-0885066611402154">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotton</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Guillamondegui</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Fleming</surname>
<given-names>SB</given-names>
</name>
<etal/>
</person-group>. <article-title>Increased risk of adrenal insufficiency following etomidate exposure in critically injured patients</article-title>. <source>Arch Surg</source>. <year>2008</year>;<volume>143</volume>(<issue>1</issue>):<fpage>62</fpage>–<lpage>67</lpage>; <comment>discussion 7</comment>.
</citation>
</ref>
<ref id="bibr14-0885066611402154">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinclair</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Broux</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Faure</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Duration of adrenal inhibition following a single dose of etomidate in critically ill patients</article-title>. <source>Intensive Care Med</source>. <year>2008</year>;<volume>34</volume>(<issue>4</issue>):<fpage>714</fpage>–<lpage>719</lpage>.</citation>
</ref>
<ref id="bibr15-0885066611402154">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuthbertson</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Sprung</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Annane</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock</article-title>. <source>Intensive Care Med</source>. <year>2009</year>;<volume>35</volume>(<issue>11</issue>):<fpage>1868</fpage>–<lpage>1876</lpage>.</citation>
</ref>
<ref id="bibr16-0885066611402154">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sprung</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Annane</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Keh</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Hydrocortisone therapy for patients with septic shock</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>(<issue>2</issue>):<fpage>111</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr17-0885066611402154">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tekwani</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Watts</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Rzechula</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Sweis</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Kulstad</surname>
<given-names>EB</given-names>
</name>
</person-group>. <article-title>A prospective observational study of the effect of etomidate on septic patient mortality and length of stay</article-title>. <source>Acad Emerg Med</source>. <year>2009</year>;<volume>16</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr18-0885066611402154">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKeating</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bali</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Dundee</surname>
<given-names>JW</given-names>
</name>
</person-group>. <article-title>The effects of thiopentone and propofol on upper airway integrity</article-title>. <source>Anaesthesia</source>. <year>1988</year>;<volume>43</volume>(<issue>8</issue>):<fpage>638</fpage>–<lpage>640</lpage>.</citation>
</ref>
<ref id="bibr19-0885066611402154">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>I</given-names>
</name>
<name>
<surname>White</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Nathanson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gouldson</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Propofol. An update on its clinical use</article-title>. <source>Anesthesiology</source>. <year>1994</year>;<volume>81</volume>(<issue>4</issue>):<fpage>1005</fpage>–<lpage>1043</lpage>.</citation>
</ref>
<ref id="bibr20-0885066611402154">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Perris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mahoney</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Anaesthesia in haemodynamically compromised emergency patients: does ketamine represent the best choice of induction agent?</article-title>. <source>Anaesthesia</source>. <year>2009</year>;<volume>64</volume>(<issue>5</issue>):<fpage>532</fpage>–<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr21-0885066611402154">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>White</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Trevor</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Ketamine–its pharmacology and therapeutic uses</article-title>. <source>Anesthesiology</source>. <year>1982</year>;<volume>56</volume>(<issue>2</issue>):<fpage>119</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr22-0885066611402154">
<label>22</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>White</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Nonopioid intravenous anesthesia</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Barash</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stoelting</surname>
<given-names>R</given-names>
</name>
</person-group> eds. <source>Clinical Anesthesia</source>. <edition>5th ed.</edition> <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2006</year>:<fpage>344</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr23-0885066611402154">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sivilotti</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ducharme</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Randomized, double-blind study on sedatives and hemodynamics during rapid-sequence intubation in the emergency department: The SHRED Study</article-title>. <source>Ann Emerg Med</source>. <year>1998</year>;<volume>31</volume>(<issue>3</issue>):<fpage>313</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr24-0885066611402154">
<label>24</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>White</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Nonopioid intravenous anesthesia</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Barash</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stoelting</surname>
<given-names>R</given-names>
</name>
</person-group> eds. <source>Clinical Anesthesia</source>.<edition>5th ed.</edition> <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2006</year>:<fpage>340</fpage>–<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr25-0885066611402154">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ploppa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kiefer</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Nohe</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Dose-dependent influence of barbiturates but not of propofol on human leukocyte phagocytosis of viable Staphylococcus aureus</article-title>. <source>Crit Care Med</source>. <year>2006</year>;<volume>34</volume>(<issue>2</issue>):<fpage>478</fpage>–<lpage>483</lpage>.</citation>
</ref>
<ref id="bibr26-0885066611402154">
<label>26</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Donati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bevan</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Neuromuscular blocking agents</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Barash</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stoelting</surname>
<given-names>R</given-names>
</name>
</person-group> eds. <source>Clinical Anesthesia</source>. <edition>5th ed.</edition> <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2006</year>:<fpage>445</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr27-0885066611402154">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayes</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Breslin</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Mirakhur</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>O'Hare</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Frequency of haemoglobin desaturation with the use of succinylcholine during rapid sequence induction of anaesthesia</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>2001</year>;<volume>45</volume>(<issue>6</issue>):<fpage>746</fpage>–<lpage>749</lpage>.</citation>
</ref>
<ref id="bibr28-0885066611402154">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donati</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>The right dose of succinylcholine</article-title>. <source>Anesthesiology</source>. <year>2003</year>;<volume>99</volume>(<issue>5</issue>):<fpage>1037</fpage>–<lpage>1038</lpage>.</citation>
</ref>
<ref id="bibr29-0885066611402154">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lerman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chinyanga</surname>
<given-names>HM</given-names>
</name>
</person-group>. <article-title>The heart rate response to succinylcholine in children: a comparison of atropine and glycopyrrolate</article-title>. <source>Can Anaesth Soc J</source>. <year>1983</year>;<volume>30</volume>(<issue>4</issue>):<fpage>377</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr30-0885066611402154">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gronert</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Theye</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Pathophysiology of hyperkalemia induced by succinylcholine</article-title>. <source>Anesthesiology</source>. <year>1975</year>;<volume>43</volume>(<issue>1</issue>):<fpage>89</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr31-0885066611402154">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazze</surname>
<given-names>RI</given-names>
</name>
<name>
<surname>Escue</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Houston</surname>
<given-names>JB</given-names>
</name>
</person-group>. <article-title>Hyperkalemia and cardiovascular collapse following administration of succinylcholine to the traumatized patient</article-title>. <source>Anesthesiology</source>. <year>1969</year>;<volume>31</volume>(<issue>6</issue>):<fpage>540</fpage>–<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr32-0885066611402154">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martyn</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>White</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Gronert</surname>
<given-names>GA</given-names>
</name>
<etal/>
</person-group>. <article-title>Up-and-down regulation of skeletal muscle acetylcholine receptors. Effects on neuromuscular blockers</article-title>. <source>Anesthesiology</source>. <year>1992</year>;<volume>76</volume>(<issue>5</issue>):<fpage>822</fpage>–<lpage>843</lpage>.</citation>
</ref>
<ref id="bibr33-0885066611402154">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Filippo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grechi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jaffe</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>High-dose vecuronium in “open-eye” emergency surgery</article-title>. <source>Minerva Anestesiol</source>. <year>1995</year>;<volume>61</volume>(<issue>11</issue>):<fpage>457</fpage>–<lpage>462</lpage>.</citation>
</ref>
<ref id="bibr34-0885066611402154">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lighthall</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Jamieson</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Katolik</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brock-Utne</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>A comparison of the onset and clinical duration of high doses of cisatracurium and rocuronium</article-title>. <source>J Clin Anesth</source>. <year>1999</year>;<volume>11</volume>(<issue>3</issue>):<fpage>220</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr35-0885066611402154">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magorian</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Flannery</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>RD</given-names>
</name>
</person-group>. <article-title>Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients</article-title>. <source>Anesthesiology</source>. <year>1993</year>;<volume>79</volume>(<issue>5</issue>):<fpage>913</fpage>–<lpage>918</lpage>.</citation>
</ref>
<ref id="bibr36-0885066611402154">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrews</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>van den Brom</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Olkkola</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Roest</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>PM</given-names>
</name>
</person-group>. <article-title>A large simple randomized trial of rocuronium versus succinylcholine in rapid-sequence induction of anaesthesia along with propofol</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>1999</year>;<volume>43</volume>(<issue>1</issue>):<fpage>4</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr37-0885066611402154">
<label>37</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Donati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bevan</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Neuromuscular blocking agents</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Barash</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stoelting</surname>
<given-names>R</given-names>
</name>
</person-group> eds. <source>Clinical Anesthesia</source>. <edition>5th ed.</edition> <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2006</year>:<fpage>426</fpage>–<lpage>429</lpage>.</citation>
</ref>
<ref id="bibr38-0885066611402154">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welliver</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McDonough</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kalynych</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Redfern</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent</article-title>. <source>Drug Des Devel Ther</source>. <year>2009</year>;<volume>2</volume>:<fpage>49</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr39-0885066611402154">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>White</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Tufanogullari</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine</article-title>. <source>Anesth Analg</source>. <year>2007</year>;<volume>104</volume>(<issue>3</issue>):<fpage>569</fpage>–<lpage>574</lpage>.</citation>
</ref>
<ref id="bibr40-0885066611402154">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Boer</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Driessen</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kerkkamp</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Heeringa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Klimek</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study</article-title>. <source>Anesthesiology</source>. <year>2007</year>;<volume>107</volume>(<issue>2</issue>):<fpage>239</fpage>–<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr41-0885066611402154">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Grounds</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Effects of thiopentone, etomidate and propofol on the haemodynamic response to tracheal intubation</article-title>. <source>Anaesthesia</source>. <year>1988</year>;<volume>43</volume>(<issue>suppl</issue>):<fpage>32</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr42-0885066611402154">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavazais</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Debaene</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Choice of the hypnotic and the opioid for rapid-sequence induction</article-title>. <source>Eur J Anaesthesiol Suppl</source>. <year>2001</year>;<volume>23</volume>:<fpage>66</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr43-0885066611402154">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Streisand</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>LeMaire</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence, duration, and plasma concentrations</article-title>. <source>Anesthesiology</source>. <year>1993</year>;<volume>78</volume>(<issue>4</issue>):<fpage>629</fpage>–<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr44-0885066611402154">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reves</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Fragen</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Vinik</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>Midazolam: pharmacology and uses</article-title>. <source>Anesthesiology</source>. <year>1985</year>;<volume>62</volume>(<issue>3</issue>):<fpage>310</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr45-0885066611402154">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tam</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Intravenous lidocaine: optimal time of injection before tracheal intubation</article-title>. <source>Anesth Analg</source>. <year>1987</year>;<volume>66</volume>(<issue>10</issue>):<fpage>1036</fpage>–<lpage>1038</lpage>.</citation>
</ref>
<ref id="bibr46-0885066611402154">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groban</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Central nervous system and cardiac effects from long-acting amide local anesthetic toxicity in the intact animal model</article-title>. <source>Reg Anesth Pain Med</source>. <year>2003</year>;<volume>28</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr47-0885066611402154">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collins</surname>
<given-names>JF</given-names>
</name>
</person-group>. <article-title>Methemoglobinemia as a complication of 20% benzocaine spray for endoscopy</article-title>. <source>Gastroenterology</source>. <year>1990</year>;<volume>98</volume>(<issue>1</issue>):<fpage>211</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr48-0885066611402154">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellis</surname>
<given-names>FD</given-names>
</name>
<name>
<surname>Seiler</surname>
<given-names>JG,</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Palmore</surname>
<given-names>MM,</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Methemoglobinemia: a complication after fiberoptic orotracheal intubation with benzocaine spray. A case report</article-title>. <source>J Bone Joint Surg Am</source>. <year>1995</year>;<volume>77</volume>(<issue>6</issue>):<fpage>937</fpage>–<lpage>939</lpage>.</citation>
</ref>
<ref id="bibr49-0885066611402154">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haynes</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Acquired methemoglobinemia following benzocaine anesthesia of the pharynx</article-title>. <source>Am J Crit Care</source>. <year>2000</year>;<volume>9</volume>(<issue>3</issue>):<fpage>199</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr50-0885066611402154">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaffery</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ananthasubramaniam</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>A rare side effect of transesophageal echocardiography: Methemoglobinemia from topical benzocaine anesthesia</article-title>. <source>Eur J Echocardiogr</source>. <year>2006</year>;<volume>9</volume>(<issue>2</issue>):<fpage>289</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr51-0885066611402154">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuschner</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Chitkara</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Canfield</surname>
<given-names>J,</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Poblete-Coleman</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Sarinas</surname>
<given-names>PS</given-names>
</name>
</person-group>. <article-title>Benzocaine-associated methemoglobinemia following bronchoscopy in a healthy research participant</article-title>. <source>Respir Care</source>. <year>2000</year>;<volume>45</volume>(<issue>8</issue>):<fpage>953</fpage>–<lpage>956</lpage>.</citation>
</ref>
<ref id="bibr52-0885066611402154">
<label>52</label>
<citation citation-type="web">
<collab collab-type="author">Patient Safety Reporting System</collab>. <year>2007</year>. <ext-link ext-link-type="uri" xlink:href="http://www.psrs.arc.nasa.gov/flashsite/index.html">http://www.psrs.arc.nasa.gov/flashsite/index.html</ext-link>. <comment>Accessed January 5, 2007</comment>.
</citation>
</ref>
<ref id="bibr53-0885066611402154">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khorasani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Candido</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Ghaleb</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Saatee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Appavu</surname>
<given-names>SK</given-names>
</name>
</person-group>. <article-title>Canister tip orientation and residual volume have significant impact on the dose of benzocaine delivered by Hurricaine spray</article-title>. <source>Anesth Analg</source>. <year>2001</year>;<volume>92</volume>(<issue>2</issue>):<fpage>379</fpage>–<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr54-0885066611402154">
<label>54</label>
<citation citation-type="web">
<article-title>Cessation of Topical Spray Benzocaine Usage to Anesthetise the Surfaces of the Nasopharynx, oropharynx, Langotracheal Region and Airway</article-title>. <source>VA Central Office 2006. AL-0609</source>; <ext-link ext-link-type="uri" xlink:href="http://www4.va.gov/ncps/alerts.html">http://www4.va.gov/ncps/alerts.html</ext-link>. <comment>Accessed July 1, 2010</comment>.
</citation>
</ref>
<ref id="bibr55-0885066611402154">
<label>55</label>
<citation citation-type="web">
<collab collab-type="author">Institute for Safe Medication Practices</collab>. <article-title>Benzocaine-containing Topical Sprays and Methemoglobinemia</article-title>. <ext-link ext-link-type="uri" xlink:href="www.ismp.org/pressroom/pr20040721_2.pdf">www.ismp.org/pressroom/pr20040721_2.pdf</ext-link> <comment>(7/1/2004). Accessed July 1, 2010</comment>.
</citation>
</ref>
<ref id="bibr56-0885066611402154">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosa</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Sverzut</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Xavier</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Lavrador</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Clinical effectiveness of lidocaine and benzocaine for topical anesthesia</article-title>. <source>Anesth Prog</source>. <year>1999</year>;<volume>46</volume>(<issue>3</issue>):<fpage>97</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr57-0885066611402154">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mainland</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>CK</given-names>
</name>
</person-group>. <article-title>Absorption of lidocaine during aspiration anesthesia of the airway</article-title>. <source>J Clin Anesth</source>. <year>2001</year>;<volume>13</volume>(<issue>6</issue>):<fpage>440</fpage>–<lpage>446</lpage>.</citation>
</ref>
<ref id="bibr58-0885066611402154">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langmack</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Pak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kraft</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Serum lidocaine concentrations in asthmatics undergoing research bronchoscopy</article-title>. <source>Chest</source>. <year>2000</year>;<volume>117</volume>(<issue>4</issue>):<fpage>1055</fpage>–<lpage>1060</lpage>.</citation>
</ref>
<ref id="bibr59-0885066611402154">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Harwood</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Woodall</surname>
<given-names>NM</given-names>
</name>
</person-group>. <article-title>Combined nebulization and spray-as-you-go topical local anaesthesia of the airway</article-title>. <source>Br J Anaesth</source>. <year>2005</year>;<volume>95</volume>(<issue>4</issue>):<fpage>549</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr60-0885066611402154">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kindler</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Schumacher</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Urwyler</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Effects of intravenous lidocaine and/or esmolol on hemodynamic responses to laryngoscopy and intubation: a double-blind, controlled clinical trial</article-title>. <source>J Clin Anesth</source>. <year>1996</year>;<volume>8</volume>(<issue>6</issue>):<fpage>491</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr61-0885066611402154">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vichitvejpaisal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gaines</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>White</surname>
<given-names>PF</given-names>
</name>
</person-group>. <article-title>Comparative effects of lidocaine, esmolol, and nitroglycerin in modifying the hemodynamic response to laryngoscopy and intubation</article-title>. <source>J Clin Anesth</source>. <year>1995</year>;<volume>7</volume>(<issue>1</issue>):<fpage>5</fpage>–<lpage>8</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>